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Abstract
Mass spectrometry (MS)-based assays for the quantification of the iron regulatory hormone hepcidin are pivotal to
discriminate between the bioactive 25-amino acid form that can effectively block the sole iron transporter ferroportin and
other naturally occurring smaller isoforms without a known role in iron metabolism. Here we describe the design, validation
and use of a novel stable hepcidin-25+40 isotope as internal standard for quantification. Importantly, the relative large mass
shift of 40 Da makes this isotope also suitable for easy-to-use medium resolution linear time-of-flight (TOF) platforms. As
expected, implementation of hepcidin-25+40 as internal standard in our weak cation exchange (WCX) TOF MS method
yielded very low inter/intra run coefficients of variation. Surprisingly, however, in samples from kidney disease patients, we
detected a novel peak (m/z 2673.9) with low intensity that could be identified as hepcidin-24 and had previously remained
unnoticed due to peak interference with the formerly used internal standard. Using a cell-based bioassay it was shown that
synthetic hepcidin-24 was, like the -22 and -20 isoforms, a significantly less potent inducer of ferroportin degradation than
hepcidin-25. During prolonged storage of plasma at room temperature, we observed that a decrease in plasma hepcidin-25
was paralleled by an increase in the levels of the hepcidin-24, -22 and -20 isoforms. This provides first evidence that all
determinants for the conversion of hepcidin-25 to smaller inactive isoforms are present in the circulation, which may
contribute to the functional suppression of hepcidin-25, that is significantly elevated in patients with renal impairment. The
present update of our hepcidin TOF MS assay together with improved insights in the source and preparation of the internal
standard, and sample stability will further improve our understanding of circulating hepcidin and pave the way towards
further optimization and standardization of plasma hepcidin assays.
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Introduction
The peptide hormone hepcidin plays a central role in regulating
dietary iron absorption and body iron distribution. Many human
diseases are associated with alterations in hepcidin concentrations.
The measurement of hepcidin in biological fluids is therefore a
promising tool in the diagnosis and management of medical
conditions in which iron metabolism is affected [1]. Hepcidin is a
25 amino-acid peptide hormone that is predominantly produced
by hepatocytes and regulates systemic iron homeostasis. Under
physiological conditions N2terminal truncated hepcidin220 and
222 peptides have been observed in the urine, but not or at low
concentrations, in plasma [2–7]. These smaller hepcidin isoforms
mostly occur in plasma in diseases that are associated with
significantly increased hepcidin concentrations, such as sepsis and
kidney failure [6,8–10]. Much is still unknown about the origin of
the smaller isoforms. Data suggest that a calcium-independent
tissue activity present in pancreas extracts might be responsible for
the systemic N-terminal truncation of hepcidin-25 to hepcidin-22,
and that dipeptidylpeptidase 4 is involved in the processing of
hepcidin-22 into hepcidin-20 [11,12]. It is however unknown
whether hepcidin isoforms can also be the result of ex-vivo
processing. Thus far, we and others measured hepcidin using a
Weak Cation Exchange Time2of2Flight Mass Spectrometry
(WCX2TOF MS) method, with the synthetic hepcidin224
(desAsp-hepcidin-25) analogue spiked into the sample as an
internal standard for quantification [5,6,10]. This hepcidin
analogue was chosen because these assays were run on low/
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medium resolution platforms such as surface-enhanced and
matrix-assisted laser desorption/ionization (SELDI/MALDI)
TOF MS platforms that need a relatively large mass difference
to separately detect two peptide peaks. Despite the slightly
different biochemical characteristics, the binding of desAsp-
hepcidin and hepcidin-25 to WCX beads were similar [5], but
different for IMAC-Cu2+ chips as applied in SELDI-TOF
measurements (hepcidin-24/hepcidin-25 ratio’s 0.71 and 0.93, as
observed by Swinkels et al. [5] and Campostrini et al. [10],
respectively). Importantly, the implementation of this internal
standard to correct for inter-assay variation proved to be very
useful and has successfully detected physiologic and pathologic
changes in serum hepcidin in patients with various disorders of
iron homeostasis [1,6,9,13–18]. However, the exact impact on the
use of desAsp-hepcidin as an internal standard on the accurate
quantification of hepcidin remained unclear, especially in disor-
ders with increased concentrations of the smaller hepcidin
isoforms.
Reliable quantitative hepcidin assays have been developed on
mass spectrometry and immunochemical platforms. The mass
spectrometry based methods can roughly be divided in those run
on low/medium resolution platforms [5,6,10,19] and those run on
high resolution platforms [20–25]. Most hepcidin assays on the
latter platforms report the use of internal standards that comprise
stable hepcidin isotopes causing mass shifts that vary between 8
and 14 Da [20–25].
At present there are considerable differences in hepcidin
measurements using the various methodologies. Our two pub-
lished international hepcidin round robins (distribution of identical
samples to allow inter-laboratory assay comparisons) revealed i)
generally high correlations between the participating methods and
ii) similar between-sample and analytical variation of most
methods [25,26]. However, absolute hepcidin concentrations
differed widely between the assays. These discrepancies might be
attributed to differences in the values that laboratories and
companies assign to the internal and external standards used for
the different methods, to impurities in these standards or to loss of
the standard during storage, e.g. by aggregation [27] or differential
adsorption of the synthetic hepcidins to tubes or other surfaces of
laboratory materials. Hence, to bridge this gap there is a need for
improved insights on accurate value assignment and optimal
handling of synthetic hepcidin standards to allow the formulation
of recommendations on this point.
In this article, we describe an update of our assay by
replacing desAsp-hepcidin (hepcidin-24) as internal standard
with a newly designed stable heavy isotope hepcidin-25 that has
an increased molecular weight of 40 Da compared to native
hepcidin-25. Notably, this relative large mass shift makes this
isotope suitable for both low/medium resolution linear time-of-
flight (TOF) platforms as well as high resolution mass
spectrometry instruments. We validated this updated assay by
assessing its reproducibility and its clinical relevance by
measuring samples from various patients groups. We moreover
investigated storage stability of hepcidin-25 and its smaller
isoforms in samples derived from different disease entities under
various conditions (anticoagulant, storage temperature and
time). An unexpected finding concerned the identification of
hepcidin-24 as a novel natural isoform in samples from kidney
disease patients. We quantified the bioactivity of this hepcidin-
24 isoform relative to bioactive hepcidin-25, and the -22 and -
20 isoforms by assessing its ability to internalize and degrade
ferroportin in a cell2based assay. Finally, we investigated the
effect of the source and handling of different internal standards
that are currently in use on the value assignment of the
hepcidin results. These data aid in the understanding of
circulating hepcidin-25 and its isoforms and the further
optimization and standardization of plasma hepcidin assays
throughout the world.
Materials and Methods
Sample Collection and Human Specimens
Ethics Statement. Use of serum and plasma from patients
and healthy donors was approved by the Medical Ethical
Committee of the district Arnhem-Nijmegen (The Netherlands)
as its use in our studies conforms to the code for proper secondary
use (‘‘goed gebruik’’) of human tissue in the Netherlands and the
declaration of Helsinki, respectively. Written informed consent
was obtained from all healthy donors.
Blank plasma and serum. Hepcidin-25 blank serum was
derived in April 2010 from an iron-depleted patient with juvenile
hemochromatosis [28]; Hepcidin-25 blank heparin-plasma was
obtained from a iron-deficient female donor in September 2012
and from the iron-depleted patient with juvenile hemochromatosis
in February 2013.
Plasma from intensive care and Nephrology
patients. The samples of patients from the intensive care unit
(IC) and the nephrology department concerned leftovers from
routine blood draws. Samples were used for measurement of
hepcidin between 4–7 hrs after blood drawing and/or pooled
and/or stored in aliquots at various temperatures for prolonged
periods of time. EDTA (n= 10) and/or heparin plasma (n= 20)
samples from IC patients were obtained in plastic tubes in
October-November 2012. Heparin and EDTA samples of patients
on hemodialysis (HD) were derived from aliquots (stored at
280uC) from a previous study collected between August and
October 2010 [16]. For use in specific experiments, plasma pools
were generated by collection of leftover samples within 24–48 hrs
(at 4uC) after routine blood draw: i) heparin plasma from 30
different IC patients was collected in November-2011, ii) heparine
plasma from 20 different nephrology patients was collected in
November 2011 to obtain 2 different pools.
Serum and plasma from healthy controls. Serum samples
from healthy controls that were used in this study concerned
leftover aliquots (stored at 280uC) that were collected in February
2011 [18]. In addition, citrate plasma, heparin plasma, EDTA
plasma and serum for stability studies was drawn in the afternoon
from healthy volunteers (n = 5), known for having fasted morning
hepcidin levels above the lower limit of detection (.0.5 nM) in
September 2012. Fresh samples were measured within 2–4 hrs
hours after blood drawing and stored in aliquots at various
temperatures for prolonged incubation.
Quality Control (QC) samples. Heparin plasma QC
samples (n = 2), high and low (HiQC2011 and LoQC2011), were
obtained in November 2011 by pooling sample leftover samples
from IC patients and iron-depleted HFE-hemochromatosis
patients, respectively. Serum QC samples (n = 2), high and low
(HiQC2009 and LoQC2009), were obtained in April 2009 from 2
blood donors from the local blood donation centre. To obtain the
high QC sample, serum of one of the donors with a native
hepcidin concentration ,1 nM was spiked with synthetic
hepcidin-25 from Peptide International (PI, Louisville, KY,
USA) to a concentration of 9 nM.
Artificial Samples
Synthetic-hepcidin (100 nM in 20% acetonitril) is spiked into
blank plasma or serum.
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MALDI-TOF MS
WCX-TOF MS was performed between October 2011 and
March 2013 as described previously by a combination of WCX
bead-based hepcidin enrichment followed by TOF-MS [6]. As
internal standards for quantification were used: i) synthetic
hepcidin-24 (custom made Peptide International, 2673.9 Da;
[5]); ii) novel custom made heavy hepcidin-25+40 (see below,
Table 1). Mass-to-charge (m/z) spectra were generated by using
MALDI-TOF MS (Microflex LT, Bruker Daltonics). Spectra were
analyzed by using Bruker Daltonics FlexAnalysis software. A
detailed protocol of this method is described in [6]. Total hepcidin
concentration was defined as the sum of hepcidin-25, -24, -22, and
-20 concentrations.
Novel Internal Standard Heavy Hepcidin-25+40
Heavy hepcidin-25+40 (hepcidin-25+40 Da;
DTHF(13C9,
15N)P(13C5,
15N)I(13C6,
15N)CI(13C6,
15N)
F(13C9,
15N)CCG(15N)CCHRSKCGMCCKT disulfide bridged)
was obtained from Peptides International (Table 1). Note that
due to an isotope content of 98% the actual mass is 1 Da less than
the theoretical mass of this peptide. Freeze dried hepcidin-25+40
was dissolved in H2O in accordance with the manual. An
0.1 nmol/L solution of hepcidin-25+40 was aliquoted in 12 mL
volumes in 200 mL polypropylene tubes and stored at 280uC until
use.
Other Synthetic Hepcidin Peptides
In certain experiments, hepcidin-25 from Peptide International
and Bachem LTD, were used (Table 1). Hepcidin-24 (custom),
hepcidin-22 and hepcidin-20 were purchased from Peptide
International. Confusingly, both Peptides International and
Bachem differed in relative peptide content of the vials. Bachem
provided the gross amount of hepcidin on the vial that (according
to the package insert) consisted of 68.6% hepcidin-25 (as assessed
by amino-acid analysis: the remaining being salts and water). In
addition, peptide contents of catalog products of Peptides
International manufactured by Peptides International itself
(USA) were lower (65–75%) than those manufactured by Peptide
Institute in Osaka, Japan (Table 1). According to manufacturers
protocol both peptides had disulfide bonds between Cys1–Cys8,
Cys2–Cys7, Cys3–Cys6, and Cys4–Cys5. Purity assessed by
HPLC was .96.1–98% for Peptide International hepcidin (-
isoforms) and.95% for Bachem hepcidin-25. Both companies did
not determine the nature of the impurities, but in the case of
peptides with multiple disulphide bridges as with hepcidin, they
may concern misfolded peptides.
Pre-treatment with Anti-hepcidin Molecules
For in vitro immune-depletion studies, we used the Anticalin
PRS-080, a highly specific and potent hepcidin antagonist
exhibiting an affinity of 50 pM for hepcidin-25 and its amino2-
terminal truncated versions including hepcidin-20 (Pieris AG,
Freising, Germany; http://www.eurocalin-fp7.eu/; [29]). Antic-
alins are engineered human lipocalins where the natural ligand
binding pocket is re-designed to bind therapeutically relevant
targets in a monovalent fashion with a molar ratio of 1:1. This has
also been experimentally confirmed for PRS-080 and other
Anticalins through X-ray analysis of crystal structures of Anticalins
in complex with their target ([30] and unpublished results). The
exquisite binding specificity and selectivity of the Anticalin was
investigated in detail with various methods including surface
plasmon resonance in which the Anticalin did not exhibit any
measurable affinity towards a range of structurally related and non
related targets ([29]; and unpublished results).
Importantly, use of PRS-080 in a non-human primate model
did effectively increase serum iron levels showing its ability to bind
and inactivate hepcidin in vivo [29]. In the in vitro experiments
described here, plasma and serum samples were incubated with
known concentrations of PRS-080 (diluted in PBS) for half an hour
at room temperature (RT), before employment in the WCX-TOF
MS assay. Concentration of PRS-080 was determined by the
UV280 method with a coefficient of variation of about 10% [31].
Hepcidin Bioactivity Assay
A stable cell line engineered for inducible expression of green
fluorescent protein (GFP)-fused human ferroportin was used as a
test system to determine hepcidin-24 activity relative to hepcidin-
25, 22 and 20. In this cell system, ferroportin internalization and
degradation provided a means to quantify hepcidin activity. The
assay was implemented basically as described by Nemeth et al.
[32,33] except that fluorescence was quantified in triplicate wells
on a microplate reader. To determine EC50 values for hepcidin-25
and hepcidin-24, a curve was fitted by nonlinear regression with a
four parameter logistic equation using Prism v5 (GraphPad).
Hepcidin Stability Experiments
Using the novel heavy hepcidin-25 internal standard, we
assessed changes in hepcidin-25 and the smaller isoforms in
various samples containing various anticoagulants ex vivo at room
Table 1. Characteristics of commercial hepcidin peptides used.
Hepcidin peptide Commercial source Product no Lot number MW (Da) pI Peptide content Purity
Heavy hepcidin-25 PI* n.a. 221-006221 2829.4{ 8.22 100%‘ .97.8%
Hepcidin-25 PI*
B
PLP-4392-s 610310
3005438
2789.4 8.22 100%‘
68.6%
.98%
.95%
Hepcidin-24 PI* n.a. 740-609191 2673.9 8.51 100%‘ 96.3%
Hepcidin-22# PI PLP-3776 PI 001055V 2436.1 8.53 74.5% 96.8%
Hepcidin-20# PI PLP-3777-PI 001041V 2191.8 8.53 67.6% 96.1%
*catalog product of Peptide International but manufactured by Peptide Institute (Osaka, Japan);
‘vialed at 100% peptide content;
{due to an isotope content of 98% the actual mass is 1 Da less than the theoretical mass of this peptide.
#delivered as 0.10 mg per vial; personal communication revealed that< 0.11 mg was pipetted in each vial. PI, Peptide International (Louisville, KY, USA); B, Bachem LTD
(St. Helens, UK); n.a., not applicable.
doi:10.1371/journal.pone.0075518.t001
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temperature (RT), 4uC, 220uC and 280uC. More specifically,
changes in hepcidin concentrations relative to those found in
freshly collected samples were determined i) at storage at RT and
4uC on day 0 (fresh samples), 1 (14–22 hrs), 2, 3, and 7 days after
sampling/storage, ii) at 220uC after 1 week, and after 1, 4 and 6
months of storage and iii) at 280uC at after 6 months of storage.
We also assessed the effect of the addition of protease inhibitors on
the stability of hepcidin concentrations of heparin plasma of IC
patients at RT during a 1 week storage. To this end, before
storage we used 1 tablet of protease inhibitor (Complete, Mini,
Roche Diagnostics, Mannheim, Germany) solved in 200 mL PBS,
of which 20 mL was added to 1 ml plasma. Finally, we used our
QC charts to assess the stability of hepcidin concentrations in
heparin plasma and serum QC aliquots stored at 280uC for 2
years.
Results and Discussion
Design of a Heavy Hepcidin-25 Isotope for Linear TOF MS
Application
Over the last years, we and others have quantified hepcidin-25
using affinity-enrichment followed by a linear TOF MS method
with synthetic hepcidin224 (desAsp-hepcidin-25) spiked into the
sample as an internal standard for quantification [5,6,10]. The
mass difference of 115.5 Da between synthetic hepcidin-24 and
native hepcidin-25 makes resolution of both peaks highly
convenient on low/medium resolution SELDI2/MALDI-TOF
MS platforms. However, due to the slightly different biochemical
characteristics (Table 1), the behavior of both peptides appeared
different in the IMAC-Cu2+ SELDI-TOF approach, which
motivated us to set-up hepcidin measurements using a weak
cation exchange (WCX-)MALDI approach in which both peptides
performed exactly the same. An important incentive of the present
study was to design a broadly applicable heavy hepcidin-25
peptide that can be used as internal standard in different assay
formats on various mass spectrometry platforms as this might
contribute to the harmonization of the different hepcidin assays
throughout the world [25]. Most assays run on high resolution MS
platforms employ hepcidin-25 standards that cause a mass shift of
hepcidin-25 between +8 and +14 Da [20–25]. As the methionine
residue in hepcidin molecules is prone to oxidation [5](+16 Da),
these relatively small mass shift internal standards would not be
adequate on low/medium resolution platforms (SELDI/MALDI-
TOF MS) due to peak interference between the internal standard
and hepcidin-25-O2. Therefore, we designed a heavy hepcidin-25
isotope with a relative large mass shift of +40 Da (molecular
weight: 2829.4 Da; see Materials & Methods) because at this
position we did not observe other interfering peaks in the WCX-
TOF MS spectra of different patient populations (data not shown).
The utility of the +40 Da hepcidin internal standard should be
verified in high resolution MS platforms as well as in low/medium
resolution TOF MS-based assays that employ other peptide
enrichment approaches. These studies are foreseen to be part of a
3rd Round Robin for serum hepcidin assays, that we will initiate in
2014.
Using hepcidin-25+40 as a new internal standard, we performed
validation experiments on different aspects of the WCX-TOF MS
assay as outlined below.
Preparation of the Internal Standard and Effect on
Hepcidin-25 Value Assignment
As quantification of native hepcidin in a sample is related to the
known concentration of the spiked internal standard, the absolute
levels of measured hepcidin are highly dependent on the value
assignment of the used internal standard. One determining factor
concerns proper dissolvent of the lyophilized peptide and whether
or not a substantial amount of the internal standard is lost by
aggregation or sticking to laboratory plastics during its prepara-
tion. Therefore, we compared the effects of three different solvents
to prepare hepcidin-25+40 stock solutions on the measured
hepcidin-25 concentration of a series of spiked blank serum
samples to which known hepcidin-25 concentrations were added.
These analyses clearly showed that significantly higher hepcidin-
25 concentrations were measured when hepcidin-25+40 was
dissolved in 5% phosphoric acid, compared to 20% acetonitril
and water as dissolvent’s (Figure 1). This finding implicates that
use of 5% phosphoric acid leads to loss of about 50% of the
peptide, while this seems to be the case for about 15% of the
peptide when water is used. As this loss is not corrected for in the
value assignment of the internal standard and the native hepcidin
peak is related to the intensity of this standard peak (which is too
low for its concentration), this results in measured values that are
false high. Based on these observations, we defined 20% acetonitril
as the best solvent to prepare stock solutions of the internal
standard as this yielded a near 1:1 ratio between the measured
hepcidin concentration and the nominal concentration (added
concentration) hepcidin (dissolved in 20% acetonitril) in the
measured samples. Therefore, 20% acetonitrile was implemented
as solvent for the internal standard in our standard operating
procedure, which was used throughout the remainder of this study.
Notably, such differences in the preparation of internal standards
could very well explain in part the high level of variation in
absolute hepcidin levels measured by different assays throughout
the world [25,26].
Quantification of Hepcidin Isoforms using Heavy
Hepcidin-25+40as Internal Standard
To assess whether hepcidin isoforms forms can also be
accurately measured using the new internal standard, hepcidin-
25+40 was spiked as internal standard into blank serum or heparin
plasma samples to which synthetic hepcidin-24, -22 and -20 was
added in known concentrations. As shown in Figure 2A, this
approached showed good linearity in measurements of all three
tested hepcidin isoforms, which was comparable to that of
hepcidin-25. The small differences in the measured values of the
Figure 1. Effect on the solvent of hepcidin-25+40 on hepcidin-
25 linearity and value assignment. Hepcidin-25+40 was dissolved in
20% acetonitril (acn), 5% phosphoric acid or water and used as internal
standards in blank serum samples containing end concentrations of 0,
0.5,1, 2, 3, 5, 7.5, 10, 15, 20 and 40 nM synthetic hepcidin-25 purchased
from Peptides International. Linearity of measured hepcidin-25 was
determined by the formulas: Y = 1.822X+0.097 (5% phosphoric acid);
Y = 1.119X+0.494 (water); Y = 0.964X+0.069 (20% acn).
doi:10.1371/journal.pone.0075518.g001
Improved Mass Spectrometry Hepcidin Assay
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e75518
different isoforms remained within the intra-run variation of the
assay (Table 2). WCX-binding characteristics and flight behavior
during TOF MS was assessed by spiking 10 nM of each of the
different synthetic hepcidin peptides to the same blank serum prior
to WCX-TOF MS. Figure 2B shows similar peak intensities of all
hepcidin peptides, which confirms that hepcidin-25+40 internal
standard is also an appropriate internal standard to quantification
hepcidin-24, -22, and -20 isoforms in our assay.
Effect of Different Plasma Matrices on Measured
Hepcidin-25 Concentration
To assess the effect of different plasma collection protocols on
the measured hepcidin-25 concentration, hepcidin-25+40 was
added to heparin plasma, EDTA plasma and citrate plasma that
was simultaneously collected from the same patients or volunteers
and frozen at 280uC until measurements. These comparisons
showed good correspondence between hepcidin-25 levels in
heparin plasma and citrate plasma (data not shown). However,
we measured slightly higher hepcidin-25 concentrations in EDTA
plasma compared to heparin plasma (Figure 3) and citrate (not
shown). We have currently no clear explanation for this difference.
Thus, to properly compare hepcidin data obtained within a study
an identical plasma matrix should be used.
Identification of Hepcidin-24 as Native Hepcidin Isoform
To further test the applicability of hepcidin-25+40 as internal
standard, it was used to quantify hepcidin-25 and its isoforms in
samples from patients for which hepcidin isoforms were expected
by WCX-TOF MS. To this purpose, we used samples from 2
heparin plasma pools that are representative for sample from
intensive care and nephrology patients. As shown in Figure 4A and
B, the resulting peptide profiles showed peaks at the m/z positions
of hepcidin-25 and its expected hepcidin-22 and hepcidin-20
isoforms. Surprisingly, these peptide spectra did also contain a
peak at m/z 2673.9 that matches the theoretical mass of hepcidin-
24 (assuming that 4 intra-molecular disulphide bridges are
present). To estimate the prevalence of this peak among
individuals from various patients groups, we investigated samples
from our bio-repository. Interestingly, the m/z 2673.9 peak was
observed in none of 5 randomly selected healthy controls [18], in 7
out of 10 patients with chronic kidney disease [9], in 7 out of 10
patients on hemodialysis [16] and in 8 out of 10 IC patients
(collected for the current study). In the patients (n = 20) with
kidney failure (either chronic kidney disease or hemodialysis) we
detected the putative hepcidin-24 peak in 3 out of 9 patients with
ferritin ,200 mg/L and in all 11 with a ferritin.200 mg/L,
suggesting a relation with iron status and/or inflammation in these
patients. To confirm the identity of the putative hepcidin-24
Figure 2. Quantification of hepcidin isoforms using hepcidin-25+40 as internal standard. A. Linearity (range 0–40 nM) for hepcidin-25,
hepcidin-24, hepcidin-22, and hepcidin-20 as determined by hepcidin-25+40 as internal standard. Linearity curves are assessed in different runs. Blank
serum (hep-24, hep-20 and hep-25) or heparin plasma (used for hep-22 as serum yields an interfering peak near the position of this isoform) was used
as matrix for the addition of the synthetic hepcidin isoforms (PI) to end concentrations of 0, 0.5,1, 2, 3, 5, 7.5, 10, 15, 20 and 40 nM. Since there is a
small interfering peak at 2191.8 Da in blank serum, the linearity curve of hepcidin-20 was corrected for the base line hepcidin-20 peak (data not
shown). Description of the lines: hepcidin-25, Y = 0.964X+0.064 (R2 = 0.9950); hepcidin-24, Y = 1.145X20.767 (R2 = 0.9975); hepcidin-22,
Y = 1.100X20.197 (R2 = 0.9998); hepcidin-20, Y = 0.867X+0.055 (R2 = 0.9998). B. WCX-TOF MS profile of blank plasma that was spiked with 10 nM
of each of the synthetic hepcidin-20, -22, -24, -25, and -25+40 peptides, which illustrates that all these hepcidin analogues have the same WCX-binding
characteristics and flight behavior during TOF MS.
doi:10.1371/journal.pone.0075518.g002
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peptide peak, we took advantage of the fact that pre-incubation of
plasma samples with the anti-hepcidin molecule PRS-080 (Antic-
alin) prevents hepcidin binding to WCX beads due to a picomolar
affinity of the Anticalin for hepcidin and thereby strong complex
formation [29]. As shown in Figure 4C, hepcidin-24 disappeared,
like hepcidin-25 and hepcidin-22, completely from the peptide
profile after PRS-080 was added to the same plasma pool from
nephrology patients that was used to generate the spectrum of
panel B. This identity confirmation shows for the first time that
hepcidin-24 can be a naturally occurring hepcidin isoform in the
circulation of intensive care and nephrology patients. Another
interesting observation concerned the fact that the intensity of the
presumed peak of hepcidin-20 at m/z 2191.8 did not completely
disappear from the spectrum after PRS-080 incubation. This
finding suggests that another hepcidin-unrelated peptide is also
present at this position as the in vitro affinity of PRS-080 is similar
for both hepcidin-20 and hepcidin-25 (our unpublished observa-
tions) and hepcidin-25, hepcidin-24 and hepcidin-22 could be
completely depleted with the employed excess of Anticalin. The
latter idea is corroborated by the peptide profiles that belong to
patients with iron deficiency anemia or iron-depleted juvenile
hemochromatosis that lack hepcidin-25, but also do contain a
detectable peak at position m/z 2191.8 (Figure 4D and E). Thus, it
is highly unlikely that the peak that is observed at this position in
the IC and nephrology samples is solely derived from the hepcidin-
20 isoform and clearly points out that hepcidin isoform analysis on
low/medium resolution platforms should be analyzed with great
care. It advocates the regular validation of the peptide identity
based on immune-depletion/capture on these platforms or MS/
MS based peptide profiling of the involved peptide peaks when
assessing different patient groups.
Bioactivity of the Newly Identified Hepcidin-24
To investigate possible clinical implications of the presence of
circulating hepcidin-24 in certain patient groups, we quantified the
ability of the newly detected hepcidin isoform to internalize and
degrade GFP-fused ferroportin in a cell-based assay [32,33],
relative to that of hepcidin-25, -22 and -20. As illustrated in
Figure 5, the EC50 for hepcidin224 was with 191.5 nM (95%
confidence interval 126.8 nM - 289.2 nM) about 10-fold higher
than that of hepcidin225 with 14.7 nM (95% confidence interval
12.2 nM –17.8 nM), indicating a 10-fold lower activity of this
newly identified hepcidin isoform. Notably, the activities of the
shorter hepcidin-22 and -20 isoforms were at least 10-fold lower
than that of hepcidin224, which is in-line with the previously
reported effects of truncation at the amino-terminus [33,34]. In
view of the fact that the hepcidin-24 levels in vivo are at least 10-
fold lower than those of hepcidin-25 (see Figure 4; data not
shown), it is not anticipated that the residual bioactivity of
hepcidin-24 contributes significantly to the ferroportin-regulating
potential in these individuals with high circulating hepcidin-25/
isoform levels.
Clinical Validation: Comparing IS Hepcidin-24 and Heavy
Hepcidin
To validate the clinical use of our updated assay, we measured
the hepcidin-25 concentrations in a variety of samples (n = 14)
using either the novel hepcidin-25+40 isotope or synthetic
hepcidin-24 as standard. We observed that values obtained by
using the heavy isotope hepcidin-25 were slightly higher in samples
that contained hepcidin isoforms than those obtained by our
former hepcidin-24 standard, nevertheless the results of both assay
had a strong correlation (Figure 6). Interestingly, upon correction
of the hepcidin-25 values obtained by using the hepcidin-24 as
internal standard, by the concentration of native hepcidin-24 in
these samples measured by the use of the hepcidin-25+40 standard,
both methodologies were nearly identical (Figure 6). This clearly
shows that use of the novel hepcidin-25+40 internal standard leads
to improved quantification in samples that contain hepcidin
isoforms. On the other hand, it shows that hepcidin-24 is a
convenient surrogate internal standard in samples that do not
contain hepcidin isoforms.
Reproducibility of the Measurement of Hepcidin-25 and
its Isoforms
To assess the robustness of the improved hepcidin assay with
hepcidin-25+40 as internal standard, we determined coefficient of
Table 2. Reproducibility of the measurement of hepcidin-25
and its isoforms of the improved hepcidin assay with the
novel hepcidin-25+40 as internal standard.*
Intra-run (n=8) Inter-run (n =8)
Hepcidin form Level (nM) CV(%) Level (nM) CV %
Hepcidin-25 2.6 2.7 2.6 8.3
3.5 3.3 10.5 4.6
7.4 3.5
10.3 2.1
Hepcidin-24 1.4 8.2 2.3 16.8
2.3 4.0
2.4 2.9
Hepcidin-22 1.4 8.6 1.4 11.6
1.7 7.8
Hepcidin-20 2.3 7.6 2.5 13.7
4.9 4.2
5.8 6.0
*Heparin samples used for intra-run experiments are the high and low QC
samples and samples from nephrology patients (n = 2). Heparin samples used
for inter-run experiments are the high and low QC samples.
doi:10.1371/journal.pone.0075518.t002
Figure 3. Comparison of hepcidin-25 concentrations measured
in EDTA plasma and heparin plasma samples from healthy
controls (n =5), hemodialysis (HD) patients (n =10) and inten-
sive care (IC) patients (n = 10). Description of the line:
Y = 1.083X+0.274 (R2 = 0.9770).
doi:10.1371/journal.pone.0075518.g003
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variations (CV’s) by repeated intra-run and inter-run measure-
ments (n = 8) of samples with different concentrations of native
hepcidin-25 and its isoforms (Table 2). These data are indicative of
a reliable TOF MS assay for assessment of hepcidin-25 and its
isoforms. They show higher CV’s for the smaller hepcidin isoforms
especially for the inter-run measurements and in the lower
concentration ranges at which these smaller isoforms are generally
observed.
Figure 4. WCX-TOF MS profiles of sample pools of patients with presumed hepcidin isoforms. Panel A, peptide profile of a heparin
plasma pool of IC patients; Panel B/C, peptide profile of heparin plasma pool of nephrology patients that were untreated (B) or pre-incubated with 1
molar excess of the anti-hepcidin molecule PRS-080 prior to WCX-TOF MS analysis (C); Panels D/E, control peptide profile of plasma from patients
with juvenile hemochromatosis and iron deficiency anemia, respectively, that lack hepcidin-25. Positions in the spectrum: hepcidin-25+40 (internal
standard), m/z 2829.4; hepcidin-25, m/z 2789.4; hepcidin-24, m/z 2673.9; hepcidin-22, m/z 2436.1; and hepcidin-20, m/z 2191.8. It should be noted
that: i) profiles from IC and nephrology patients both clearly contain the m/z 2673.9 peak at the presumed position of hepcidin-24; ii) this peak
disappears completely from the profile after incubation with PRS-080, similar to hepcidin-25/-22; iii) hepcidin-25+40 does not disappear from the
profile as it was added after the PRS-080 incubation period, which limits complex formation; iv) the intensity of the presumed peak of hepcidin-20 at
m/z 2191.8 after PRS-080 incubation decreases but does not disappear completely suggesting that another hepcidin-unrelated peptide is also
present at this position; v) the peptide spectra of patient that lack hepcidin-25 also contain a peak at m/z 2191.8 (calculated between 1–2 nM),
providing further evidence for the unlikeliness that this peak is solely derived from hepcidin-20.
doi:10.1371/journal.pone.0075518.g004
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Value Assignment: Effect of Vendor of Synthetic
Hepcidin-25
To better understand the cause of different absolute hepcidin
concentrations that are measured by different hepcidin assays
throughout the world [25], we used the hepcidin-25+40 standard to
quantify synthetic hepcidin peptides from either Bachem or
Peptides International that were spiked in blank serum with
10 nM of synthetic hepcidin-25 (according to the package inserts
of the vendors). In the samples spiked with synthetic hepcidin from
Peptides International we observed a mean concentration of
9.91 nM (n= 2) hepcidin-25, whereas this was 6.86 nM (n= 2) for
the synthetic peptide from Bachem (Figure 7). These findings
corroborate previous reported data and indicate that a significant
difference in value assignment exists between the hepcidin-25
peptides from these two vendors, even when corrected towards a
100% peptide content of hepcidin-25 [25]. Consequently, if both
would be used to quantify hepcidin, than the assay in which the
Bachem peptide was used would give about 1.5-fold higher
concentrations than when an internal standard from Peptides
International was used.
Value Assignment Assessed by Immuno-depletion with
Hepcidin Antagonists
To get an impression of the accuracy of the absolute hepcidin
concentrations measured by our assay, we aimed to compare the
decrease in hepcidin concentration in relation to the addition of
known concentrations of the hepcidin-specific Anticalin PRS-080
that blocks binding of hepcidin to WCX beads during the affinity
enrichment step of our assay. As shown in Figure 8, we observed a
near equimolar decrease in hepcidin upon addition of increasing
concentrations of PRS-080 for six separate native samples that did
or did not contain hepcidin isoforms with concentrations between
10 nM and 40 nM of total hepcidin (sum of concentrations of
hepcidin-25 and isoforms). More specifically, our observations
were consistent with a molar ratio PRS-080 to hepcidin-25 of
1.53:1, suggesting that the absolute concentrations of hepcidin that
are measured by our WCX-TOF MS assay are slightly too high
assuming that all PRS-080 and hepcidin molecules have a
confirmation that enables complex formation. Importantly, these
data show that the hepcidin concentrations measured by the
WCX-TOF MS assay come near to the real absolute values and
are at least in the correct order of magnitude. The fact that we
measure slightly higher levels than expected indicates that a minor
fraction of the hepcidin-25+40 peptide is lost by sticking to pipette
tips and/or tubes during preparation of the standard and does not
end up in the stock solution of the internal standard, which thus is
assigned a somewhat too high concentration. Based on our current
experiments we predict that our thus far reported levels should be
corrected by a factor 0.65 to approximate the absolute hepcidin
levels in a sample. However, it should be emphasized that in
biomedical studies the relative differences in hepcidin levels
between study groups are more important than the absolute levels
and that most currently available hepcidin assays are able to
accurately do so, but do not allow inter-assay comparisons [25].
Effect of Sampling Material and Storage Conditions on
Hepcidin-25 and its Isoforms
Storage at room temperature. To assess the stability of
hepcidin in serum and plasma matrices, we kept samples from
intensive care patients (n = 20) and healthy controls (n = 5) at room
temperature for 0–7 days followed by WCX-TOF MS analysis
using the hepcidin-25+40 internal standard. For heparin plasma
samples, the results showed that hepcidin-25 gradually decreased
at a rate that was highly sample dependent (Table 3, Figure S1A).
For the samples at day 1 and day 7, the mean decrease in
hepcidin-25 for the 5 controls and 20 intensive care patients was
90% (CV, 8% ) and 55% (CV, 23%), respectively (Table 3).
Besides hepcidin-25 we also measured the smaller hepcidin-
isoforms (Figure S1B-D, Table 3). In control samples, only the
isoform hepcidin-20 emerged in time. However, the quantitative
data of the isoform in time were considered not to be reliable since
levels remained below 1 nM, and thus were associated with high
inter-run CV’s.
Interestingly, as illustrated by Figure 9, for samples from
intensive care patients, the initial decrease in hepcidin-25 was
paralleled by an increase in the smaller hepcidin isoforms during
this period. For these patients, the respective mean increase of the
hepcidin isoforms at day 7 were 116% (31%) for hepcidin-24, 160
(23%) for hepcidin-22, and 164% (41%) for hepcidin-20 (Table
S1). However, the total amount of hepcidin decreased to 229%
(17%) at day 7 (Table 3), suggesting that hepcidin-isoforms are
Figure 5. Hepcidin-mediated ferroportin internalization. Differ-
ent concentrations of synthetic hepcidin-25, -24, -22 and -20 (indicated
in nM on the horizontal axis) were added to the growth medium of a
stable cell line that expresses green fluorescent protein-fused
ferroportin (GFP-FPN). Hepcidin-mediated GFP-FPN internalization and
degradation was quantified by measuring cellular fluorescence levels in
arbitrary units.
doi:10.1371/journal.pone.0075518.g005
Figure 6. Comparison of hepcidin concentrations obtained by
the respective internal standards hepcidin-24 and hepcidin-
25+40, with and without correction for native hepcidin-24
concentrations. Samples (n = 14) consisted of serum samples from
healthy controls (n = 3), heparin plasma from nephrology patients
(n = 7), heparin plasma high and low QC pools, serum high and low QC
pools. Description of the lines: hepcidin-25 (IS HEP-24),
Y = 0.878X+0.059 (R2 = 0.9959); hepcidin-25 (IS HEP-24), with hep-24
correction, Y = 1.041X20.425 (R2 = 0.9960).
doi:10.1371/journal.pone.0075518.g006
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degraded in smaller pieces that are not detected in our mass-
spectrometry setup (Figure 9, Table 3).
For hepcidin-25 similar results were obtained for serum, EDTA
plasma and citrate plasma of 5 healthy control subjects (Figure S2).
Addition of protease inhibitors to heparin samples of IC patients
(n = 10) prevented hepcidin-25 processing to a certain extend but
did not block its decrease completely (Table S1).
Thus, since a 0–7 day stay of samples on the laboratory bench
of samples with and without hepcidin isoforms results in ex-vivo
changes in hepcidin-25 and its smaller isoforms, delays in
measurements or in aliquoting for storage at lower temperatures
should be prevented. These results differ from those of Itkonen
et al. [35] who found hepcidin-25 levels of serum from 12 healthy
controls to be stable for 1 day at room temperature.
Storage at 4uC. In heparin and EDTA plasma samples from
intensive care patients (n = 10) and healthy controls (n = 5) and
citrate-plasma and serum samples from healthy controls (n = 5)
that were kept at 4uC for 0–7 days, concentrations of
hepcidin225, remained stable (Table S2/Figure S2). The same
holds for total hepcidin and hepcidin isoforms of the intensive care
patients (with the exception for hepcidin-20 in EDTA plasma, see
Table S2). However, in these samples we cannot fully exclude
small changes in hepcidin isoforms in time due to the relatively
high inter-run CV’s of their measurement. In controls concentra-
tions of hepcidin isoforms remained ,1 nM in time (data not
shown).
Altogether, these data merely agree with the previously reported
6-day stability found for serum in 12 healthy controls [35] and
indicate that samples can be shipped at 4uC in case this
temperature can be guaranteed during transport of less than 7
days.
Storage at 220uC. Hepcidin-25 concentrations in i) serum
and heparin plasma, EDTA plasma, and citrate plasma samples of
healthy controls (n = 5) stored at 220uC did not change
significantly for at least 6 months and ii) EDTA plasma and
heparin plasma samples of 10 intensive care patients and 5
controls stored at 220uC remained stable for at least 4 weeks
(Tables S3 and S4). In time, concentrations of hepcidin isoforms
remained ,1 nM for controls (data not shown) and did not
change in time for IC patients.
We observed no differences between the various anticoagulants
used. We observed, however, a small non significant decrease of
hepcidin-25 upon freezing (e.g. for heparin samples at 7 days: total
intensive care and control (n = 15): 95% (CV 8%) relative to fresh
Figure 7. Peak Intensity of synthetic Hepcidin-25 of Peptides
International (Vendor A; top panel) and Bachem (Vendor B;
bottom panel) spiked to blank serum (to obtain a 10 nM
concentration) and measured by WCX-TOF MS, using hepcidin-
25+40 from Peptides International as internal standard. The
theoretical concentrations of hepcidin-25 used in these experiments
were adjusted towards 100% peptide content, based on the
information provide in the package inserts of the respective Vendors
(see Table 1). Hep-25, m/z 2789.4; Hep-25+40 (internal standard), m/z
2829.4.
doi:10.1371/journal.pone.0075518.g007
Figure 8. Hepcidin quantification by WCX-TOF MS in human
samples that were pre-incubated with 0, 5 or 10 nM of PRS-080
to block binding of hepcidin to the WCX beads. Decrease in
hepcidin concentration was determined by measurement of 6 different
samples, with total hepcidin concentrations between 10 and 40 nM,
incubated with PRS-080. Dotted line indicates the theoretically
expected 1:1 ratio. Description of the line: Y = 0.655X+0.013
(R2 = 0.9373).
doi:10.1371/journal.pone.0075518.g008
Table 3. Relative change of hepcidin at RT in heparin
plasma*.
Hepcidin level after one day at RT (%)
Hep-25 Hep-24 Hep-22 Hep-20 Total-Hep
average 90 120 127 115 98
CV 8 21 14 25 5
+2 SD 103 169 163 171 108
22 SD 76 71 91 58 87
n= 24 15 13 18 11
Hepcidin level after one week at RT (%)
Hep-25 Hep-24 Hep-22 Hep-20 Total-Hep
average 55 104 150 138 71
CV 23 29 29 38 17
+2 SD 80 164 237 242 94
22 SD 30 44 62 34 47
n= 24 15 13 18 11
*Relative change in hepcidin-25, -24, -22 and -20 concentrations in heparin
plasma samples expressed as percentage of the respective concentrations in
fresh samples. Samples were from 19 intensive care (IC) patients and 5 controls
and kept for 1 day and 7 days (1 week) at RT. Results ,1.0 nM were removed
from the calculations, among which are the results of the isoforms of 5 controls.
Only results from samples with complete serial measurements are included.
doi:10.1371/journal.pone.0075518.t003
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samples, Table S3). Hepcidin isoforms did not change significantly
in time. However, it should be noted that the reproducibility of the
measurements of the smaller isoforms at low concentrations is low,
especially the measurements of hepcidin-20 in EDTA plasma
samples (Table 2, Table S3). Thus, hepcidin measurements by
WCX-TOF MS are not influenced by storage at 220uC for at
least 4 weeks, except for a possible small decrease in hepcidin-25
upon freezing. These data corroborate previous findings of a
stability for serum at last 42 days in healthy controls [35].
Moreover, storage of EDTA plasma samples at 220uC does
provide unreliable hepcidin-20 results with WCX-TOF MS.
Storage at 280uC. Hepcidin-25 results in QC serum samples
measured by our former hepcidin-24 standard remained stable for
2 years at 280uC. Thereafter CV’s increased, and control values
regularly were out of range, necessitating re-analyses of the
samples (Figure S3). This increase of CV’s of hepcidin-25
measurements are most likely due to increasing noise in the MS
profile upon prolonged storage.
Hepcidin-25 results in QC heparin plasma samples stored at
280uC and measured with the heavy hepcidin standard are stable
for at least 1.5 years (Figure S3).
Storage of serum, heparin, EDTA and citrate plasma of 5
healthy volunteers results in a small but not significant average
decrease of 4–6% in hepcidin-25 concentrations after 6 months
(Table S5).
We conclude that hepcidin-25 results are not changed during 2
years of storage at 280uC, except for a possible small decrease
upon freezing. However, after 2 years storage at 280uC, hepcidin
results become less precise and individual measurements might
become less reliable. Average results for a population may not be
affected, but existing differences in hepcidin levels between groups,
or correlations of hepcidin with other parameters might be more
difficult to assess. These data extend previous reports describing
hepcidin stability at 280uC for at least 6–8 months [23,36,37].
Concluding Remarks
Our WCX-TOF MS assay has proven to be an accurate and
reproducible methodology to quantify hepcidin-25 and provides
physiologically relevant results that were published in more than
60 biomedical studies over the last five years (see: www.
hepcidinanalysis.com). Here we show that the implementation of
the hepcidin-25+40 isotope, which replaces hepcidin-24 as a
internal standard, further improves the test characteristics of this
methodology, especially with respect to samples from patients with
hepcidin isoforms. Our data on the stability of hepcidin-25 and its
isoforms under various conditions will be helpful in the design of
clinical studies. The implementation of the hepcidin-25+40 now
also allows the identification and quantification of hepcidin-24 as a
novel isoform in specific patient groups. Importantly, we have
pinpointed critical steps in the handling and preparation of the
internal standards in general to provide clues for a more accurate
determination of the absolute hepcidin concentration. We strongly
believe that different sources and protocols for preparation of
hepcidin standards is most strongly contributing to the differences
in values between methodologies as observed in the world-wide
round robins [25,26]. The difference in hepcidin results obtained
with standards from different vendors suggests issues with value
assignment of these materials, while the choice of dissolvent
significantly affects the recovery of the reference peptide.
Suboptimal materials (lower starting amount) and protocols (lost
of standard due to sticking to laboratory plastics) all lead to a lower
actual concentration of the hepcidin standard than expected and
used to calculate the measured hepcidin concentration. This leads
to false high measured hepcidin levels and this observation implies
that the assays that report the lowest hepcidin concentration may
be most accurate in terms of absolute quantification. Interestingly,
in the Round Robins for serum hepcidin our WCX-TOF MS
(Method II in [26]; MS1 in Table 2 and onwards in [25]), was
among the assays that measured lowest absolute hepcidin
concentrations. Our titration experiments with the hepcidin-
specific Anticalin PRS-080 seems to indicate that even our
optimized protocols do not allow full recovery of the internal
standard and that we may still measure about 1.53-fold higher
hepcidin levels than actually present in a sample. Nevertheless, the
hepcidin-25+40 peptide could aid in the desired harmonization of
hepcidin throughout the world. As the relative large mass shift of
40 Da makes this isotope suitable for easy-to-use medium
resolution linear TOF platforms, but can also be used on high-
resolution mass spectrometry platforms as well as immunoassays.
Therefore, this peptide is a strong candidate to be introduced as
higher order reference materials to validate the different reference
peptides that are in use throughout the world. Taken together, our
present study aids in the understanding of circulating hepcidin-25
and its isoforms and provide important leads for the further
harmonization of plasma hepcidin assays.
Supporting Information
Figure S1 Changes in concentrations of hepcidin-25 (A),
hepcidin isoforms (B, C, D) in heparin samples from IC patients
(n = 19 in black) and healthy controls (n = 5, in red) kept for 0–7
days at room temperature. Only samples with complete serial
measurements are included; results ,1 nM were excluded. None
of the freshly collected samples from healthy control subjects
contained hepcidin isoforms levels .1 nM.
(TIF)
Figure S2 Changes in concentrations of hepcidin-25 in heparin,
EDTA and citrate plasma as well as serum in samples from the
Figure 9. Changes in time at RT of hepcidin-25, 24, 22, and 20
and their sum (total hepcidin) in a representative heparin
sample of an IC patient to illustrate that decrease in hepcidin-
25 levels is accompanied by an increase in hepcidin-24, -22,
and -20 levels. Similar observations for an extended set of samples are
shown in Figure S1. Note that the total amount of hepcidin decreases
despite the increase in hepcidin isoform levels.
doi:10.1371/journal.pone.0075518.g009
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same 5 healthy controls (collected at the same moment) kept for 0–
7 days at room temperature (RT) or 4uC.
(TIF)
Figure S3 Control charts of results from HiQC samples
measured throughout time. A, serum; B, plasma. QC samples
were aliquoted and stored at 280uC, a fresh aliquot was used for
each measurement. Deviation starts to increase after 2 years for
the serum QC sample, the plasma QC sample is still stable after
1.5 years.
(PDF)
Table S1 Relative change of hepcidin-25, -24, -22, -20
concentrations in heparin samples from 10 intensive care (IC)
patients after 1 day (A) and 1 week (7 days; B) at room
temperature (RT) with and without addition of protease inhibitors.
(DOC)
Table S2 Relative change of hepcidin-25, -24, -22 and -20
concentrations in heparin and EDTA plasma samples from 10
intensive care (IC) patients and 5 controls after 1 day (A) and after
1 weeks (7 days; B) at 4uC. *Results of samples with measured
hepcidin ,1.0 nM were deleted from the calculations. Samples
from controls did not contain hepcidin isoform levels .1.0 nM;
#, Measurements of hepcidin-20 in stored EDTA plasma proved
unreliable due to the variable and unexplained appearance of an
additional peak of similar mass in the WCX-TOF MS profile.
(DOC)
Table S3 Relative change of hepcidin-25, -24, -22 and -20
concentrations in heparin and EDTA plasma samples from 10
intensive care (IC) patients and 5 controls after 1 week (A) or 1
month (4 weeks; B) at 220uC. *Results of samples with measured
hepcidin ,1.0 nM were deleted from the calculations. Samples
from controls did not contain hepcidin isoform levels .1.0 nM;
#, Measurements of hepcidin-20 in stored EDTA plasma proved
unreliable due to the variable and unexplained appearance of an
additional peak of similar mass in the WCX-TOF MS profile, e.g.
for EDTA plasma samples in 7 out of 10 patients, intra-individual
changes in hepcidin-20 in time (fresh, week 1, week 4) showed an
outlier (defined as 1 out of 3 serial measurements .100% different
from other 2 measurements).
(DOC)
Table S4 Relative change of hepcidin-25 concentration in
heparin -, EDTA-, and citrate plasma and serum from 5 controls
after 1 week (wk), 1 month (mnt), 4 months (mnts) and 6 mnts at
220uC.
(DOC)
Table S5 Relative change of hepcidin-25 concentration in
heparin -, EDTA-, and citrate plasma and serum from 5 controls
after 6 months at 280uC.
(DOC)
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